Fajardo Carlos, Macedo Marta, Buha Tonka, De Donato Marcos, Costas Benjamin, Mancera Juan Miguel
Department of Biology, Faculty of Marine and Environmental Sciences, Instituto Universitario de Investigación Marina (INMAR), Campus de Excelencia Internacional del Mar (CEI·MAR), University of Cadiz (UCA), 11510 Puerto Real, Spain.
Interdisciplinary Centre of Marine and Environmental Research, University of Porto (CIIMAR), 4450-208 Matosinhos, Portugal.
Animals (Basel). 2025 May 27;15(11):1570. doi: 10.3390/ani15111570.
Biotechnological advances applied to the generation of genetically modified (GM) animals have shown the potential to develop innovative solutions for different challenges in key areas such as agriculture and human medicine. Despite its enormous potential, the deployment of genetic modification in animals, and its subsequent commercialization, does not meet the same public acceptance as GM plant-derived products, which are currently widely adopted around the world. In this review, we highlight the main examples of GM and gene-edited animal-derived products already approved by the FDA and discuss the regulatory context inherent to such processes, including the risk-based assessment analysis based on a case-by-case evaluation. Moreover, cases of GM animals already approved by other jurisdictions around the world are also discussed.
应用于转基因动物培育的生物技术进展已显示出为农业和人类医学等关键领域的不同挑战开发创新解决方案的潜力。尽管具有巨大潜力,但动物基因改造及其后续商业化并未获得与转基因植物衍生产品相同的公众接受度,转基因植物衍生产品目前在全球广泛采用。在本综述中,我们重点介绍了已获美国食品药品监督管理局(FDA)批准的转基因和基因编辑动物衍生产品的主要实例,并讨论了此类过程所固有的监管背景,包括基于逐案评估的风险评估分析。此外,还讨论了世界其他司法管辖区已批准的转基因动物案例。